argenx SE (ARGX) Earnings Call Transcripts
argenx SE's Latest Earnings Call - June 23, 2026
In the second quarter of 2026, argenx SE (ARGX:BE) reported significant advancements in its clinical pipeline, particularly regarding the autoimmune myositis indication for Vyvgart. The company is on track for a Phase III data readout in Q3 2026, with management expressing strong confidence in the potential for positive results. Revenue and earnings details were not disclosed, but the focus on myositis, particularly immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM), indicates a robust commercial opportunity, with management highlighting a potential blockbuster status for both indications. The company has refined its regulatory strategy, planning to analyze IMNM and DM separately, which could enhance its chances for approval.
Reported metrics
| Metric | Value |
|---|---|
| Phase II Enrollment | 89 patients (beat) |
| Primary Endpoint p-value | 0.0004 (beat) |
| Patient Years of Experience | 25,000 patient years (positive) |
| Projected IMNM Patients | 20,000 patients (positive) |
| Projected DM Patients | 40,000 patients (positive) |
| TIS Improvement Score | 50% improvement (beat) |
Guidance from management
Management is focused on the upcoming Phase III data readout in Q3 2026 and is optimistic about the potential for positive results in both IMNM and DM. The regulatory strategy has been refined to analyze these indications separately, enhancing the likelihood of approval.
What management said
Yes. And just a follow-up to that. We've been thinking about her disease course, but the course in IMNM in general, right, is we know it's very aggressive. So could you talk to us a little bit about how you think about the urgency to treat there?
And these patients have a privilege of getting to in a very specialized sort of tertiary center, but I would imagine that could be somewhat disparate depending on where you are and your access to care.
What analysts pressed on
Analysts expressed concerns regarding the differentiation in efficacy between IMNM and DM, particularly given the aggressive nature of IMNM. There were questions about the potential impact of the steroid tapering protocol on the placebo group and how that might affect the overall trial outcomes.
Main topics on the call
- Phase III Data Expectations — Management emphasized the upcoming Phase III data readout in Q3 2026, stating, "We have strong conviction in our Phase II data" and expressing optimism for positive outcomes in both IMNM and DM. The Phase III trial is de...
- Regulatory Strategy Update — The company has updated its regulatory strategy to analyze IMNM and DM separately, which was described as a "clear path forward" by management. This decision was influenced by the strong data observed in IMNM during Phas...
- Market Opportunity in Autoimmune Myositis — Management highlighted the significant unmet need in autoimmune myositis, stating, "There are no treatment options approved" for IMNM, with a potential market of 20,000 patients. The urgency to treat these patients was e...
- Efficacy and Safety Profile — The Phase II data showed a strong efficacy signal, particularly in IMNM, with management stating, "We saw a clear signal in DM that gives us the confidence to move forward." The safety profile is also considered robust, ...
Read the full argenx SE transcript (June 23, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About argenx SE
argenx SE (ARGX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on ENXTBR and is based in BE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 74 calls on record spanning January 14, 2020 to July 27, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 74 argenx SE earnings call transcripts on record, spanning January 14, 2020 to July 27, 2026. Based on this history, argenx SE reports quarterly. The most recent call on file is dated July 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ARGX
- Exchange
- ENXTBR
- Country
- BE
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 74
- First call
- January 14, 2020
- Most recent
- July 27, 2026
- Reporting cadence
- quarterly